The international journal of neuropsychopharmacology
-
Int. J. Neuropsychopharmacol. · Jul 2020
Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data.
Esketamine nasal spray was recently approved for treatment-resistant depression. The current analysis evaluated the impact of symptom-based treatment frequency changes during esketamine treatment on clinical outcomes. ⋯ These findings support individualization of esketamine nasal spray treatment frequency to optimize treatment response in real-world clinical practice.